{"schema_version":"secwatch.filing_event.v1","accession":"0001077183-25-000151","form_type":"8-K","ticker":"NEO","cik":"0001077183","company_name":"NEOGENOMICS INC","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.277732+00:00","generated_at":"2026-05-17T23:30:44.654609+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeoGenomics Q2 revenue up 10% to $181M but net loss widens to $45M; cuts full-year guidance","bullets":["Revenue $181M (+10% YoY); clinical revenue grew 16% (13% ex-Pathline).","Net loss widened 142% to $45M including $20M impairment charges.","Adjusted EBITDA flat at $10.7M vs $10.9M last year.","Full-year 2025 revenue guidance cut to $720-$726M (prev $747-$759M); Adj EBITDA guidance lowered to $41-$44M.","Acquired Pathline for $8M cash plus $1M contingent consideration in April 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001077183-25-000151","json":"https://secwatch.observer/filing/0001077183-25-000151.json","markdown":"https://secwatch.observer/filing/0001077183-25-000151.md","text":"https://secwatch.observer/filing/0001077183-25-000151.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1077183/000107718325000151/0001077183-25-000151-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1077183/000107718325000151/neo-20250729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:30:44.654609+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}